Teva Pharmaceutical Industries - 34 Year Stock Price History | TEVA
Historical daily share price chart and data for Teva Pharmaceutical Industries since 1990 adjusted for splits and dividends. The latest closing stock price for Teva Pharmaceutical Industries as of November 19, 2024 is 16.81.
- The all-time high Teva Pharmaceutical Industries stock closing price was 67.06 on July 27, 2015.
- The Teva Pharmaceutical Industries 52-week high stock price is 19.31, which is 14.9% above the current share price.
- The Teva Pharmaceutical Industries 52-week low stock price is 9.35, which is 44.4% below the current share price.
- The average Teva Pharmaceutical Industries stock price for the last 52 weeks is 15.05.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Teva Pharmaceutical Industries Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2024 |
15.6100 |
10.6700 |
18.9600 |
10.6700 |
16.8100 |
61.02% |
| 2023 |
9.1624 |
9.5300 |
11.3700 |
7.2000 |
10.4400 |
14.47% |
| 2022 |
8.6581 |
8.3300 |
11.2100 |
6.8600 |
9.1200 |
13.86% |
| 2021 |
10.0923 |
10.3400 |
12.8100 |
7.9000 |
8.0100 |
-16.99% |
| 2020 |
10.4263 |
9.5600 |
13.4500 |
6.6900 |
9.6500 |
-1.53% |
| 2019 |
11.4964 |
15.8500 |
20.0100 |
6.1600 |
9.8000 |
-36.45% |
| 2018 |
20.9176 |
19.1100 |
25.6500 |
14.5900 |
15.4200 |
-18.63% |
| 2017 |
25.1752 |
36.2877 |
36.7524 |
11.1652 |
18.9500 |
-46.01% |
| 2016 |
48.5120 |
61.4736 |
62.0008 |
33.9156 |
35.0968 |
-43.20% |
| 2015 |
57.4253 |
51.7518 |
67.0558 |
50.5644 |
61.7937 |
16.73% |
| 2014 |
46.9148 |
36.1043 |
53.7549 |
35.7635 |
52.9393 |
47.29% |
| 2013 |
34.4799 |
32.4379 |
37.1235 |
32.4379 |
35.9429 |
10.36% |
| 2012 |
35.9346 |
36.8548 |
39.4116 |
32.2286 |
32.5688 |
-5.63% |
| 2011 |
38.5499 |
44.2345 |
47.3106 |
30.0250 |
34.5118 |
-21.23% |
| 2010 |
46.0024 |
48.0507 |
53.7257 |
39.3724 |
43.8142 |
-6.06% |
| 2009 |
39.9240 |
35.0590 |
46.7142 |
34.0725 |
46.6394 |
33.28% |
| 2008 |
36.8902 |
38.2007 |
40.4406 |
30.9902 |
34.9932 |
-7.37% |
| 2007 |
32.8761 |
25.2087 |
38.0625 |
25.2087 |
37.7780 |
50.73% |
| 2006 |
29.2785 |
35.2174 |
35.2174 |
23.8544 |
25.0635 |
-27.08% |
| 2005 |
26.6383 |
23.1818 |
36.3841 |
21.3405 |
34.3703 |
45.04% |
| 2004 |
23.6841 |
22.8660 |
27.1200 |
18.7397 |
23.6976 |
5.76% |
| 2003 |
20.0211 |
15.4815 |
24.2331 |
13.6685 |
22.4076 |
47.25% |
| 2002 |
12.7675 |
12.1533 |
15.5918 |
10.2099 |
15.2174 |
25.60% |
| 2001 |
11.9083 |
12.9320 |
14.3495 |
9.9910 |
12.1159 |
-15.74% |
| 2000 |
10.4833 |
6.8561 |
15.3062 |
6.2984 |
14.3787 |
104.78% |
| 1999 |
4.7438 |
4.1278 |
7.0216 |
3.8962 |
7.0216 |
76.63% |
| 1998 |
3.9448 |
4.7305 |
4.8708 |
3.1335 |
3.9754 |
-13.74% |
| 1997 |
5.3845 |
4.8025 |
6.5470 |
4.1343 |
4.6087 |
-5.58% |
| 1996 |
4.0556 |
4.4656 |
4.8939 |
2.9571 |
4.8812 |
8.70% |
| 1995 |
3.4050 |
2.3136 |
4.5624 |
2.0783 |
4.4907 |
92.58% |
| 1994 |
2.6080 |
2.9030 |
3.2868 |
2.1614 |
2.3319 |
-19.33% |
| 1993 |
2.3858 |
2.2125 |
3.2127 |
1.7820 |
2.8905 |
37.70% |
| 1992 |
1.3099 |
1.0536 |
2.1407 |
0.9589 |
2.0991 |
134.77% |
| 1991 |
0.7238 |
0.5536 |
0.9342 |
0.5183 |
0.8941 |
65.02% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.044B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
